RY

Rhythm Pharmaceuticals, Inc. Earnings Recaps

RYTM 3 recaps
Next earnings: November 3, 2026 (estimated) · full calendar
Q2 2026 Aug 6, 2026

Rhythm Pharmaceuticals’ shares rose 7.7% following the quarter, driven by a promising start to the U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO) and encouraging early clinical data for its next-generation MC4R agonist, RM-718.

Key takeaways
  • Since FDA approval in March, over 400 start forms have been received from roughly 300 prescribers for IMCIVREE in HO, indicating strong early demand.
  • Published Phase III HO TRANSCEND trial results and accompanying New England Journal of Medicine editorial have raised disease awareness and credibility of IMCIVREE among clinicians and payers.
  • RM-718 Phase II open-label data show a meaningful mean BMI reduction of 11.6% at 16 weeks in HO patients, with a favorable tolerability profile and no generalized hyperpigmentation reported.
  • Two patients discontinued RM-718 early due to injection site reactions and nausea; overall patient retention remains solid with 8 of 11 enrolled still on therapy.
  • Rhythm is progressing toward anticipated regulatory submissions and launches in Japan and Europe, leveraging an established rare disease commercial platform.
Full recap
Q1 2026 May 6, 2026

The stock surged 12.9% following a quarter that demonstrated clear initial traction with the newly approved acquired hypothalamic obesity (HO) indication, a significantly larger market opportunity than Bardet-Biedl syndrome (BBS). Early launch metrics and payer receptivity for HO drove optimism about Rhythm’s commercial expansion and long-term growth potential.

Key takeaways
  • Q1 revenues reached $60 million, reflecting steady growth in the base BBS business despite it being an ultra-rare disease.
  • The acquired HO launch is off to a solid start with over 150 patient start forms submitted since the March approval, indicating strong physician and payer engagement.
  • Commercial infrastructure expanded substantially, with sales reps increasing from 16 (BBS) to 42 (HO), signaling Rhythm’s commitment to capturing the larger HO patient population (~10,000 estimated in U.S. and Europe).
  • Positive early data from Japan and anticipated regulatory approval before year-end reinforce the global growth thesis for HO.
  • Upcoming clinical data presentations and planned Phase III trial initiation aim to sustain momentum and expand the therapeutic portfolio in HO and Prader-Willi syndrome.
Full recap
Q3 2025 Nov 6, 2025

Rhythm Pharmaceuticals reported strong Q3 2025 performance, highlighted by significant growth in IMCIVREE revenue and strategic advancements in their product pipeline, positioning the company for upcoming launches.

Key takeaways
  • IMCIVREE sales reached $51.3 million, marking a 10% increase in reimbursed therapy patients.
  • Successful completion of a $189 million equity offering in July to strengthen the balance sheet ahead of key regulatory developments.
  • Regulatory filings for hypothalamic obesity (HO) accepted by both the FDA and EMEA, with a PDUFA date set for December 20, 2025.
  • Upcoming preliminary results from the Phase II trial in Prader-Willi syndrome expected by year-end, aimed at demonstrating efficacy in BMI reduction.
  • Expansion of the commercial team in preparation for the HO launch, targeting an estimated 10,000 patients in the U.S. market.
Full recap

Go deeper on RYTM and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.